Compare

Scholar Rock/$SRRK

1D1W1M3M6MYTD1Y5YMAX

About Scholar Rock

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Ticker
$SRRK
Sector
Health
Primary listing
NASDAQ
Employees
289

Scholar Rock Metrics

BasicAdvanced
$5.5B
-
-$3.39
0.79
-

What the Analysts think about Scholar Rock

Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Analyst projections of the future price of Scholar Rock stock.

Bulls say / Bears say

The FDA has approved Isembyld for adults and children aged two and older with SMA who are already on SMN2-targeted treatment. In the pivotal trial, the recommended dose improved motor-function scores by 2.2 points versus placebo, supporting a differentiated add-on treatment. (Scholar Rock, Inc.)
International growth could add to the US opportunity: Scholar Rock resubmitted its European application using the manufacturing site that supported US approval, with a European committee opinion expected in the first half of 2027. Japan’s regulator has agreed that no local clinical trial is needed before a planned filing. (Scholar Rock, Inc., Scholar Rock, Inc.)
The pipeline offers potential beyond the current SMA market: the company has started a Phase 2 apitegromab study in FSHD and is testing its separate myostatin drug SRK-439 in a Phase 1 study. Both are early-stage opportunities, rather than established sources of future sales. (Scholar Rock, Inc.)
Fractures are a notable safety concern: they occurred in 9% of patients on the approved dose versus 2% on placebo. The FDA also requires rapid reporting of fracture cases and a pregnancy safety study. (Scholar Rock, Inc., SEC)
Early sales may lag clinical interest because insurers must approve coverage and infusion centres need time to arrange treatment. Ahead of the first post-approval results, analysts expected only $1.43 million of third-quarter revenue, with reimbursement and billing delays potentially stretching the time to a first infusion beyond 60 days. (Investing.com)
Scholar Rock remains loss-making and may need more capital if sales do not ramp quickly: it reported a $215 million net loss in the first half of 2026 and said its cash would fund operations only into the second half of 2027 under its current plan. The company also said it would need additional capital to complete development and commercialisation of its programmes. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.

Scholar Rock Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Scholar Rock Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.